Race to stop cancer before it starts: new drug trial aims to delay deadly myeloma
NCT ID NCT07393282
Summary
This study is testing whether an experimental drug called linvoseltamab can delay the development of active multiple myeloma better than an existing drug, daratumumab. It involves 270 people diagnosed with high-risk smoldering multiple myeloma, a condition that often progresses to active cancer. The main goal is to see which treatment keeps patients cancer-free longer and improves their quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK SMOLDERING MULTIPLE MYELOMA (HR-SMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.